AIM ImmunoTech CEO buys 24,000 shares at $0.208

AIM ImmunoTech Inc. (AIM) reported that CEO and President Thomas K. Equels purchased 24,000 shares of common stock in a open market or private transaction on September 17, 2026, at $0.208 per share, bringing his directly held position to 126,822 shares.

Rhea-AI Filing Summary

AIM ImmunoTech Inc. (AIM) reported that CEO and President Thomas K. Equels purchased 24,000 shares of common stock in a open market or private transaction on September 17, 2026, at $0.208 per share, bringing his directly held position to 126,822 shares.

No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Buyer: 24,000 shares

Net Buy 1 txn

Insider Equels Thomas K

Role CEO & President

Bought 24,000 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	24,000	$0.208	$5K

Holdings After Transaction: Common Stock — 126,822 shares (Direct)

Key Figures

Shares purchased: 24,000 shares Purchase price per share: $0.208 per share Shares owned after transaction: 126,822 shares

3 metrics

Shares purchased 24,000 shares Common stock purchased on September 17, 2026

Purchase price per share $0.208 per share Open market or private transaction on September 17, 2026

Shares owned after transaction 126,822 shares Directly held common stock following the reported purchase

Key Terms

Rule 10b5-1 trading plan, open market or private transaction, Form 4

3 terms

Rule 10b5-1 trading plan regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction market

"Purchase in open market or private transaction"

Form 4 regulatory

"as stated in the Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AIM ImmunoTech (AIM) report for Thomas K. Equels?

AIM ImmunoTech reported that CEO and President Thomas K. Equels purchased 24,000 shares of common stock on September 17, 2026 in a open market or private transaction at $0.208 per share.

How many AIM (AIM) shares does Thomas K. Equels hold after this Form 4 transaction?

After the reported purchase, Thomas K. Equels directly holds 126,822 shares of AIM ImmunoTech common stock, as stated in the Form 4 filing.

Was the AIM ImmunoTech (AIM) insider trade made under a Rule 10b5-1 plan?

No. The filing indicates the Rule 10b5-1 checkbox is not affirmed, so this purchase by Thomas K. Equels was not reported as being made under a Rule 10b5-1 trading plan.

What price did the AIM (AIM) CEO pay per share in the reported purchase?

Thomas K. Equels purchased AIM ImmunoTech common stock at $0.208 per share for 24,000 shares in the September 17, 2026 transaction.

Is the AIM ImmunoTech (AIM) CEO’s ownership direct or indirect after this transaction?

The Form 4 states that Thomas K. Equels’ 126,822 shares of AIM ImmunoTech common stock are held with direct ownership following the reported purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 08:30 AM Accepted by SEC EDGAR 09/18/2026 - 08:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Equels Thomas K

(Last) (First) (Middle)

2117 SOUTHWEST HIGHWAY 484

(Street)

OCALA FLORIDA 34473

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AIM ImmunoTech Inc. [ AIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2026		P		24,000	A	$0.208	126,822	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Thomas K Equels	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)